Reported Sunday, JELMYTO Demonstrates Remarkable 86% Recurrence-Free Survival Rate At 24 Months For All Studied Patient And Disease Characteristics
Reported Sunday, JELMYTO Demonstrates Remarkable 86% Recurrence-Free Survival Rate At 24 Months For All Studied Patient And Disease Characteristics
周日报道，JELMYTO显示，所有研究的患者和疾病特征在24个月内无复发存活率均为86％
- There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location
- RFS Was 100% in Patients who Received Maintenance therapy vs 61% for Patients Who Did Not Receive Maintenance Therapy
- "The 86% recurrence-free survival rate at the 24-month mark among low-grade UTUC patients (n=53) exhibited a favorable response to the initial induction of this new treatment," said Adam Feldman, M.D., M.P.H., Urologic Oncologist in the Department of Urology at Massachusetts General Hospital, and Director of the Combined Harvard Urologic Oncology Fellowship. "Notably, there seems to be no discernible difference in disease recurrence based on tumor characteristics or timing of administration, including primary chemoablation or post-endoscopic ablation. These results offer additional evidence for the clinical utility of JELMYTO and may also offer hope for improved long-term outcomes for our patients."
- 在化疗消融或内窥镜消融术的用法、肿瘤大小、多焦点或肿瘤位置方面，RFS没有差异
- 接受维持治疗的患者的RFS为100％，而未接受维持治疗的患者的RFS为61％
- 麻省总医院泌尿外科肿瘤科医生、哈佛泌尿外科肿瘤联合奖学金主任亚当·费尔德曼说：“低度UTUC患者（n=53）在24个月大关时无复发存活率为86％（n=53）对这种新疗法的初始引入表现出良好的反应。”“值得注意的是，根据肿瘤特征或给药时间，包括原发性化疗或内窥镜后消融术，疾病复发似乎没有明显的区别。这些结果为JELMYTO的临床用途提供了更多证据，也可能为我们的患者带来改善长期疗效的希望。”